Akari Therapeutics Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
12
- Stock Symbol
-
CLA
- Investments
-
2
- Share Price
-
$3.36
- (As of Friday Closing)
Akari Therapeutics General Information
Description
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Contact Information
Website
www.akaritx.comCorporate Office
- 75/76 Wimpole Street
- London W1G 9RT
- England, United Kingdom
Corporate Office
- 75/76 Wimpole Street
- London W1G 9RT
- England, United Kingdom
Akari Therapeutics Timeline
Akari Therapeutics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.36 | $3.57 | $2.56 - $3.78 | $39.7M | 12M | -$2.99 |
Akari Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (20,094) | (10,086) | (17,790) | (17,431) |
| Net Income | (20,133) | (10,008) | (17,748) | (17,424) |
| Total Assets | 5,076 | 4,355 | 13,832 | 11,648 |
| Total Debt | 1,000 | 0 | 0 | 0 |
Akari Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Akari Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Akari Therapeutics Comparisons
Industry
Financing
Details
000000
000000
Akari Therapeutics Competitors (62)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Omeros | Formerly VC-backed | Seattle, WA | 000 | 00000 | 000000000 00 | 00000 |
| Gilead Sciences | Formerly VC-backed | Foster City, CA | 00000 | 000.00 | 0000 | |
| BeiGene | Formerly PE-Backed | Cambridge, MA | 0000 | 00.000 | 000000&0 | 00.000 |
| Innovent Biologics | Formerly PE-Backed | Suzhou, China | 0000 | 00.000 | 000000000 | 00.000 |
| Regulus Therapeutics | Formerly VC-backed | San Diego, CA | 00 | 00000 | 00000000 | 00000 |
Akari Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Akari Therapeutics Patents
Akari Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2010247814-A1 | Lipid-polymer conjugates, their preparation and uses thereof | Active | 11-May-2009 | 0000000000 | |
| AU-2010247814-B2 | Lipid-polymer conjugates, their preparation and uses thereof | Inactive | 11-May-2009 | 0000000000 | 0 |
| EP-2429532-A1 | Lipid-polymer conjugates, their preparation and uses thereof | Inactive | 11-May-2009 | 0000000000 | |
| EP-2429532-A4 | Lipid-polymer conjugates, their preparation and uses thereof | Inactive | 11-May-2009 | 0000000000 | 0 |
| US-20150065467-A1 | Use of lipid conjugates in the treatment of diseases or disorders of the eye | Inactive | 14-Nov-2006 | A61K31/661 |
Akari Therapeutics Executive Team (14)
| Name | Title | Board Seat |
|---|---|---|
| Samir Patel MD | Board Member, Interim Chief Executive Officer & President | |
| Miles Nunn | Chief Scientific Officer | |
| John Neylan MD | Chief Medical Officer | |
| Wendy DiCicco | Interim Chief Financial Officer |
Akari Therapeutics Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Donald Williams | Self | Board Member | 000 0000 |
| Michael Grissinger | Self | Board Member | 000 0000 |
| Mohamed Wael Hashad | Self | Board Member | 000 0000 |
| Raymond Prudo-Chlebosz MD | Self | Chairman & Board Member | 000 0000 |
| Samir Patel MD | Akari Therapeutics | Board Member, Interim Chief Executive Officer & President | 000 0000 |
Akari Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Akari Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Akari Therapeutics Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Peak Bio | 05-Mar-2024 | 0000000000 | Biotechnology | ||
| Celsus Therapeutics | 18-Sep-2015 | Merger/Acquisition | 000.00 | Biotechnology | 000 00000 |
Akari Therapeutics FAQs
-
When was Akari Therapeutics founded?
Akari Therapeutics was founded in 2005.
-
Who is the CEO of Akari Therapeutics?
Samir Patel MD is the CEO of Akari Therapeutics.
-
Where is Akari Therapeutics headquartered?
Akari Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Akari Therapeutics?
Akari Therapeutics has 12 total employees.
-
What industry is Akari Therapeutics in?
Akari Therapeutics’s primary industry is Drug Discovery.
-
Is Akari Therapeutics a private or public company?
Akari Therapeutics is a Public company.
-
What is Akari Therapeutics’s stock symbol?
The ticker symbol for Akari Therapeutics is CLA.
-
What is the current stock price of Akari Therapeutics?
As of 06-Sep-2024 the stock price of Akari Therapeutics is $3.36.
-
What is the current market cap of Akari Therapeutics?
The current market capitalization of Akari Therapeutics is $39.7M.
-
Who are Akari Therapeutics’s competitors?
Omeros, Gilead Sciences, BeiGene, Innovent Biologics, and Regulus Therapeutics are some of the 62 competitors of Akari Therapeutics.
-
What is Akari Therapeutics’s annual earnings per share (EPS)?
Akari Therapeutics’s EPS for 12 months was -$2.99.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
